COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50%
Novo Nordisk to Slash U.S. List Prices for Ozempic and Wegovy in 2027
U.S. List-Price Cuts Announced for 2027
COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year.
Drugs Affected: Ozempic and Wegovy
(Reporting by Louise Rasmussen, editing by Terje Solsvik)


